Status:

UNKNOWN

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

Lead Sponsor:

Arizona Oncology Services

Conditions:

Localized Breast Cancer

Localized Prostate Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Participants will be diagnosed with localized prostate or breast cancer and be scheduled to undergo external beam radiation therapy. Participants will either receive a placebo or organic germanium to ...

Detailed Description

With the increasing public use of complementary medicines, most researchers agree that there is a compelling need to study the safety and efficacy of these agents in humans by means of appropriately d...

Eligibility Criteria

Inclusion

  • Histologically-confirmed diagnosis of breast (females only) or prostate cancer
  • Zubrod performance status of 0-1.
  • Patients must be ≥ 18 years of age.
  • Scheduled to undergo definitive radiation therapy (either brachytherapy or external beam)
  • Patients may have received or be receiving hormonal therapy. Prior chemotherapy is allowed as long as the patient has recovered from any toxicity. Planned future chemotherapy is also allowed after the one month evaluation.
  • Hgb ≥ 10 g/dl, BUN \< 25 mg and creatinine \< 1.5 mg
  • Patient must be able to comply with treatment regimen.
  • Patient must complete the pre-treatment quality of life questionnaires.
  • Women of childbearing potential must have a pre-treatment pregnancy test; women of childbearing potential and men able to father children must use non-hormonal-based birth control while on study.
  • Patients must sign study-specific informed consent prior to study entry.

Exclusion

  • Known allergies or reactions to Organic germanium
  • Prior irradiation other than basal cell cancer of skin
  • Current or past history of metastasis
  • Current history of uncontrolled hypertension, insulin dependent or uncontrolled diabetes, cardiovascular disease unless controlled and stable for 6 months or more, bleeding disorders, or autoimmune disorders such as fibromyalgia, chronic fatigue syndrome or lupus
  • Current use of corticosteroids or erythropoietin
  • Patients currently taking Organic germanium, or who have taken Organic germanium within the past three months
  • Pregnant or lactating women, as treatment involves unforeseeable risks to the participant and to the embryo or fetus
  • Patients who are unable to complete quality of life questionnaires
  • Male breast cancer patients

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2012

Estimated Enrollment :

101 Patients enrolled

Trial Details

Trial ID

NCT00651417

Start Date

April 1 2005

End Date

December 1 2012

Last Update

June 23 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Arizona Oncology Services

Phoenix, Arizona, United States, 85013